What is IN8bio, Inc. (INAB) stock price today?

IN8bio, Inc. (INAB) is currently trading at $1.34, down 2.9% today.

What is INAB P/E ratio?

IN8bio, Inc.'s P/E ratio is -0.75. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is INAB return on equity (ROE)?

IN8bio, Inc.'s return on equity (ROE) is -91.18%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is IN8bio, Inc.'s market cap?

IN8bio, Inc. has a market capitalization of $12.85M.

NCM · Biotechnology

IN8bio, Inc. (INAB) Stock

$1.34 -2.90% NCM: INAB Healthcare

Valuation

Metric	Value
Price	$1.34
Market Cap	$12.85M
P/E Ratio	-0.75
P/B Ratio	1.48
P/S Ratio	0.00
EPS (TTM)	$-4.44
52-Week High	$2.73
52-Week Low	$0.88
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-91.18%
ROA	-85.85%
ROCE	-96.68%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.12
Current Ratio	9.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-15.0M	$-29.0M	$-30.0M	$-30.0M	$-20.0M
Net Profit	$-15.0M	$-29.0M	$-30.0M	$-30.0M	$-19.0M
EPS	$-23.41	$-40.81	$-30.14	$-17.05	$-4.44
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$42.0M	$33.0M	$34.0M	$21.0M	$32.0M
Total Liabilities	$4.0M	$10.0M	$9.0M	$6.0M	$5.0M
Cash	$37.0M	$18.0M	$21.0M	$11.0M	$27.0M
Borrowings	$2.0M	$6.0M	$5.0M	$5.0M	$3.0M

Latest News

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma GlobeNewswire · Jul 9, 2026 IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks · Jun 4, 2026 IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies GlobeNewswire · Jun 3, 2026 IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 GlobeNewswire · Jun 1, 2026 IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma GlobeNewswire · May 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-14.0M	$-24.0M	$-23.0M	$-24.0M	$-13.0M
Investing Cash Flow	$-1.0M	$-7.0M	$-1.0M	$0	$0
Financing Cash Flow	$-3.0M	$0	$0	$5.0M	$0
Net Cash Flow	$19.0M	$-19.0M	$3.0M	$-10.0M	$16.0M
Free Cash Flow	$-14.0M	$-28.0M	$-24.0M	$-24.0M	$-13.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.14
FCF Yield	-108.73%
Quick Ratio	8.21
Interest Coverage	0.00
Return 1Y	-33.49%
Return 3Y	-97.04%
Return 5Y	—

Ownership

Insiders Held13.40%

Institutions Held38.11%

Institutions Float Held44.01%

Institutional Holder	Shares	Report Date
Alyeska Investment Group, L.p.	944,319	2026-03-31
Franklin Resources, Inc.	914,531	2026-03-31
683 Capital Management LLC	724,637	2026-03-31
Stonepine Capital Management, LLC	663,412	2026-03-31
Bios Capital Management, LP	167,805	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXPAcurx Pharmaceuticals, Inc.	$1.27	+1.60%	-0.36	$5.46M	0.00%
APREAprea Therapeutics, Inc.	$0.60	+8.28%	-0.64	$7.48M	0.00%
APVOAptevo Therapeutics Inc.	$1.79	-0.56%	-0.01	$3.91M	0.00%
BCDABioCardia, Inc.	$1.04	-1.89%	-1.54	$15.48M	0.00%
GLTODamora Therapeutics, Inc.	$21.58	-3.36%	-0.17	$34.47M	0.00%

About IN8bio, Inc.

IN8bio, Inc. is led by CEO Tai-Wei, employs 18 people, headquartered in US, publicly traded since 2021.

IN8bio, Inc. (INAB) stock trades at $1.34 with a market capitalization of $12.85M. The stock is valued at a price-to-earnings (P/E) ratio of -0.75, price-to-book of 1.48, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.88 and $2.73, and currently trades 50.9% below its 52-week high.

On profitability, IN8bio, Inc. generates a return on equity (ROE) of -91.18%, return on capital employed of -96.68%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides